Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

KaloBios Buys Chagas Drug With Eye On Priority Review Voucher

This article was originally published in Scrip

Executive Summary

No one else in the biopharmaceutical industry is viewed more negatively right now than Martin Shkreli, but the former hedge fund investor and current Turing Pharmaceuticals CEO is having a positive effect on KaloBios Pharmaceuticals Inc., whose stock surged when Shkreli took over the company and rose again after the once-troubled biotech firm bought a drug for Chagas disease.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst